A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
NCT00051051
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Female, at least 18 years of age
- Histologically confirmed diagnosis of breast cancer
- Metastatic (Stage IV) disease
- Progressive or recurrent disease following the most recent therapy
- No more than 2 different, prior cytotoxic chemotherapy regimens for metastatic disease
- At least one measurable target lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) that has not been irradiated
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, determined within 2 weeks prior to randomization
- Estimated life expectancy of > 12 weeks
- Capable of giving written informed consent
- Capable of swallowing intact CI-1033 capsules
- Capable of understanding and adhering to the protocol requirements
- No prior exposure to CI-1033 or other agents that target the erbB receptor family (such as Herceptin, Iressa, Tarceva, IMC-C225, and EKB-569)
- No known hypersensitivity reaction to tyrosine kinase inhibitors
- Adequate liver, renal, or bone marrow function determined within 2 weeks prior to randomization
- No cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin)
- No immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments
- No hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments (6 weeks for megestrol acetate)
- Patients must have recovered from the acute effects of any radiation therapy or surgery
- No treatment with any other investigational therapy within 4 weeks prior to baseline disease assessments
- No history of any cancer other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years
- No patients with untreated brain metastases or patients that have not recovered from treatment for brain metastases
- No known malabsorption syndrome or other condition that may impair absorption of study medication
- No comorbidity or condition which compromises compliance with this protocol as judged by the investigator or that would significantly complicate interpretation of the safety profile of CI-1033
- No patients having reproductive potential who are not using a method of birth control or who are pregnant or breastfeeding or have a positive pregnancy test during baseline
Prior exposure to CI-1033 or other agents that target the erbB receptor family; cytotoxic
chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas
or mitomycin); immunotherapy (including Herceptin) or other biologic therapy within 2 weeks
prior to baseline disease assessments; hormone therapy (including hormone replacement
therapy) within 4 weeks prior to baseline disease assessments; 6 weeks for megestrol
acetate (to exclude the possibility of a hormone-withdrawal response); patients with
untreated brain metastases.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Manresa, Barcelona
- Terrassa, Barcelona
- San Sebastián, Donostia
- Las Palmas de Gran Canaria, Gran Canaria
- Alcorcón, Madrid
- Fuenlabrada, Madrid
- Leganés, Madrid
- San Sebastián de los Reyes, Madrid
- Palma de Mallorca, Mallorca
- Pamplona, Navarra
- Santa Cruz de Tenerife, Tenerife
- Bilbao, Vizcaya
- A Coruña,
- Albacete,
- Alicante,
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Barcelona,
- Cáceres,
- Córdoba,
- León,
- Lugo,
- Madrid,
- Madrid,
- Murcia,
- Málaga,
- Salamanca,
- Sevilla,
- Toledo,
- Valencia,
- Valencia,
- Valencia,
- Valencia,
- Zaragoza,
- Zaragoza,
- Elche, Alicante
- Sagunto, Valencia
- Ávila,
- St. Louis, Missouri
- Nagoya, Aichi
- Kashiwa, Chiba
- Matsuyama, Ehime
- Sapporo, Hokkaido
- Akashi, Hyogo
- Yokohama, Kanagawa
- Ōsaka-sayama, Osaka
- Minato-Ku, Tokyo
- Chiba,
- Fukuoka,
- Osaka,
- Seoul,
- Seoul,
- Singapore,
- Taipei,
- Taipei,
- Singapore,
- Gyeonggi-do,
- Soeul,
- Tokyo,
- Gyeonggi-do,
- Taipei,
- Gyeonggi-do,
- Birmingham, Alabama
- Scottsdale, Arizona
- Rochester, Minnesota
- Saint Louis, Missouri
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer | |||
Official Title ICMJE | A Phase II, Randomized, Open-Label Study of Single Agent CI-1033 in Patients With Metastatic Breast Cancer | |||
Brief Summary | CI-1033 is an experimental drug that acts as an inhibitor of erbB (EGFR) receptors, which may be involved in tumor growth. The primary objective of this study is to assess the antitumor activity of CI-1033 in patients with metastatic breast cancer. Patients with histologically confirmed metastatic (Stage IV) breast cancer and who have received no more than 2 prior cytotoxic chemotherapy regimens are eligible for this study. CI-1033 is administered orally. Patients are required to have blood tests periodically while receiving treatment and will be closely monitored throughout the study for possible side effects and response to treatment. Patients may not have received any prior treatment with other agents that target erbB receptors, including Herceptin (trastuzumab) or Iressa (gefitinib). | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Breast Neoplasms | |||
Intervention ICMJE | Drug: CI-1033 | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 168 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | May 2005 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria: Prior exposure to CI-1033 or other agents that target the erbB receptor family; cytotoxic chemotherapy within 3 weeks prior to baseline disease assessments (6 weeks for nitrosoureas or mitomycin); immunotherapy (including Herceptin) or other biologic therapy within 2 weeks prior to baseline disease assessments; hormone therapy (including hormone replacement therapy) within 4 weeks prior to baseline disease assessments; 6 weeks for megestrol acetate (to exclude the possibility of a hormone-withdrawal response); patients with untreated brain metastases. | |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Belgium, Canada, France, Ireland, Italy, Spain, Sweden, United Kingdom, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00051051 | |||
Other Study ID Numbers ICMJE | 1033-011 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | September 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |